Please assess the completion status of the following clinical trial:

Trial Title: Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of an infection consistent with complicated skin and skin structure infections.~Exclusion Criteria:~* Known or suspected hypersensitivity to any study medication or other related anti-infective medication~* Any known or suspected condition or concurrent treatment contraindicated by the prescribing information~* Previous enrollment in this study~* Treatment with any investigational drug within 30 days before enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vancomycin plus Ceftazidime (Type: ACTIVE_COMPARATOR): Vancomycin 1g q12h as 1h infusions plus Ceftazidime 1g q8h in 2h-infusions, 7-14d
- Ceftobiprole medocaril (Type: EXPERIMENTAL): Ceftobiprole medocaril 500mg q8h as 2h infusions, 7-14d

Based on this trial design, predict the completion outcome and termination type (if applicable).